Veterans’ RightsAn independent resource for veterans
← All decisions
Denied

The Board has determined that the Veteran's seborrheic dermatitis does not warrant a rating in excess of 30 percent as it affects less than 40% of his total body or exposed areas, and no systemic therapy is required.

The deciding factor: The medical evidence shows that the Veteran’s skin condition affects less than 20% of his total body area and has not required systemic therapy such as corticosteroids or immunosuppressive drugs during the past 12 months.

Claimed conditions
chronic diarrhea, fatigue, memory loss, sleep disorder, headaches, irritable bowel syndrome, joint pain
How they argued it
Not specified
Exposure basis
None
Rating assigned
30%
Decision date
March 19, 2013
Citation
1309228

This is a plain-language summary generated by AI from a public Board of Veterans’ Appeals decision. It can contain errors — always verify against the original. Look up the original decision on VA.gov (opens in a new tab) using citation 1309228.

What this means for you

A denial is a starting point, not the end of the road. You can see why this claim fell short — and, if you are still inside the one-year window, the appeal lanes that may remain open to you.

What you can do next

Related decisions

Other Board decisions on a similar condition or argued the same way.

Free starter guide for your own claim

Reading this because you were denied or under-rated? Get the plain-English next steps — your appeal options, the deadline that protects you, and how appeals like yours turn out. One email, no spam.

We will only use this to send the guide. No spam, unsubscribe any time. We never sell your information.

We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.

This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.